# Isolation methods influence the biological properties of Wharton’s Jelly-derived mesenchymal stem cells: A comparative study of yield, viability, proliferation, differentiation potential, and proteomic profiles

**Authors:** Jens Long Nguyen, Samih Mohamed-Ahmed, Ragda Saleem, Kamal Mustafa, Niyaz Al-Sharabi, Mariann Haavik Lysfjord Bentsen

PMC · DOI: 10.1371/journal.pone.0345081 · 2026-03-20

## TL;DR

This study compares different methods to isolate Wharton’s Jelly-derived stem cells and finds that one method with a growth factor produces the most viable and functional cells.

## Contribution

The study identifies a robust isolation method for WJ-MSCs that enhances viability and metabolic resilience.

## Key findings

- The non-scraped explant method with bFGF yields highest cell viability and proliferation.
- Proteomic analysis reveals bFGF-treated cells are enriched for metabolic pathways.
- Enzymatic isolation without bFGF leads to early culture failure in most donors.

## Abstract

Mesenchymal stem cells derived from Wharton’s Jelly (WJ-MSCs) are an attractive cell source for regenerative medicine due to high proliferative capacity, non-invasive accessibility, and minimal ethical constraints. However, their therapeutic efficacy may vary with isolation technique and culture conditions.

We compared three WJ-MSC isolation methods; two explant approaches (non-scraped and scraped) and one enzymatic method – each cultured with or without basic fibroblast growth factor (bFGF). WJ-MSCs were obtained from three full-term umbilical cords, and subsequently evaluated for cell viability, proliferation kinetics, immunophenotypic surface marker expression, multilineage differentiation potential, and proteomic profiles through mass spectrometry coupled with bioinformatics analyses.

All methods produced viable WJ-MSCs, although enzymatic isolation without bFGF resulted in early culture failure in 2/3 donors and was excluded from downstream analyses. Highest viability was observed with the non-scraped explant method supplemented with bFGF, and bFGF significantly enhanced proliferation by reducing cell doubling time. All groups consistently expressed canonical MSC markers, along with WJ-MSC-specific surface proteins. Osteogenic differentiation was robust across all groups, whereas adipogenic differentiation was limited. Proteomic profiling revealed 2,372 proteins commonly expressed across all groups, indicating a largely stable core proteome, with isolation- and bFGF-dependent modulation observed primarily at the pathway level. Gene set enrichment analysis showed that bFGF-treated cultures were enriched for metabolic pathways, including oxidative phosphorylation and fatty acid metabolism, whereas bFGF-free and enzymatic isolation methods showed increased inflammatory and stress-related signatures. Differential expression analysis further identified 36 proteins uniquely regulated by isolation method and bFGF treatment, associated with cell adhesion, tissue morphogenesis, and immunomodulatory functions.

This study clarifies how isolation- and growth factor–driven effects shape the functional properties and paracrine identity of WJ-MSCs. The non-scraped explant method with bFGF emerges as a robust, reproducible approach, yielding high-viability, phenotypically stable, and metabolically resilient MSCs. These findings provide a framework for standardized WJ-MSC production optimized for regenerative and immunomodulatory applications.

## Linked entities

- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** FHL2 (four and a half LIM domains 2) [NCBI Gene 2274] {aka AAG11, DRAL, FHL-2, SLIM-3, SLIM3}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, CSRP1 (cysteine and glycine rich protein 1) [NCBI Gene 1465] {aka CRP, CRP1, CSRP, CYRP, D1S181E, HEL-141}, NEO1 (neogenin 1) [NCBI Gene 4756] {aka IGDCC2, NGN, NTN1R2}, HLA-A (major histocompatibility complex, class I, A) [NCBI Gene 3105] {aka HLAA}, CSF2 (colony stimulating factor 2) [NCBI Gene 1437] {aka CSF, GMCSF}, TPM1 (tropomyosin 1) [NCBI Gene 7168] {aka C15orf13, CMD1Y, CMH3, HEL-S-265, HTM-alpha, LVNC9}, WNT5B (Wnt family member 5B) [NCBI Gene 81029], PDGFC (platelet derived growth factor C) [NCBI Gene 56034] {aka FALLOTEIN, SCDGF}, PDGFRB (platelet derived growth factor receptor beta) [NCBI Gene 5159] {aka CD140B, IBGC4, IMF1, JTK12, KOGS, OPDKD}, LMOD1 (leiomodin 1) [NCBI Gene 25802] {aka 1D, 64kD, D1, MMIHS3, SM-LMOD, SMLMOD}, ICAM1 (intercellular adhesion molecule 1) [NCBI Gene 3383] {aka BB2, CD54, P3.58}, PLD3 (phospholipase D family member 3) [NCBI Gene 23646] {aka AD19, HU-K4, HUK4, SCA46}, HLA-B (major histocompatibility complex, class I, B) [NCBI Gene 3106] {aka AS, B-4901, HLAB}, CAPN2 (calpain 2) [NCBI Gene 824] {aka CANP2, CANPL2, CANPml, mCANP}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, MAPK9 (mitogen-activated protein kinase 9) [NCBI Gene 5601] {aka JNK-55, JNK2, JNK2A, JNK2ALPHA, JNK2B, JNK2BETA}, CSRP2 (cysteine and glycine rich protein 2) [NCBI Gene 1466] {aka CRP2, LMO5, SmLIM}, MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, HK1 (hexokinase 1) [NCBI Gene 3098] {aka CNSHA5, HK, HK1-ta, HK1-tb, HK1-tc, HKD}, MCAM (melanoma cell adhesion molecule) [NCBI Gene 4162] {aka CD146, HEMCAM, METCAM, MUC18, MelCAM}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, NAGLU (N-acetyl-alpha-glucosaminidase) [NCBI Gene 4669] {aka CMT2V, MPS-IIIB, MPS3B, NAG, UFHSD}, LTF (lactotransferrin) [NCBI Gene 4057] {aka GIG12, HEL110, HLF2, LF}, CFL2 (cofilin 2) [NCBI Gene 1073] {aka NEM7}, CDH2 (cadherin 2) [NCBI Gene 1000] {aka ACOGS, ADHD8, ARVD14, CD325, CDHN, CDw325}, VCAM1 (vascular cell adhesion molecule 1) [NCBI Gene 7412] {aka CD106, INCAM-100}, SERPING1 (serpin family G member 1) [NCBI Gene 710] {aka C1IN, C1INH, C1NH, HAE1, HAE2}, IGHG2 (immunoglobulin heavy constant gamma 2 (G2m marker)) [NCBI Gene 3501], HSP90AA1 (heat shock protein 90 alpha family class A member 1) [NCBI Gene 3320] {aka EL52, HEL-S-65p, HSP86, HSP89A, HSP90A, HSP90N}, LTBP3 (latent transforming growth factor beta binding protein 3) [NCBI Gene 4054] {aka DASS, GPHYSD3, LTBP-3, LTBP2, STHAG6, pp6425}, PCNA (proliferating cell nuclear antigen) [NCBI Gene 5111] {aka ATLD2}, ANXA1 (annexin A1) [NCBI Gene 301] {aka ANX1, LPC1}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, MYH9 (myosin heavy chain 9) [NCBI Gene 4627] {aka BDPLT6, DFNA17, EPSTS, FTNS, MATINS, MHA}, CXCL3 (C-X-C motif chemokine ligand 3) [NCBI Gene 2921] {aka CINC-2b, GRO3, GROg, MIP-2b, MIP2B, SCYB3}, HRG (histidine rich glycoprotein) [NCBI Gene 3273] {aka HPRG, HRGP, THPH11}, CFI (complement factor I) [NCBI Gene 3426] {aka AHUS3, ARMD13, C3BINA, C3b-INA, FI, IF}, CD81 (CD81 molecule) [NCBI Gene 975] {aka CVID6, S5.7, TAPA1, TSPAN28}, PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, MDK (midkine) [NCBI Gene 4192] {aka ARAP, MK, NEGF2}, ISG15 (ISG15 ubiquitin like modifier) [NCBI Gene 9636] {aka G1P2, IFI15, IMD38, IP17, UCRP, hUCRP}, A2M (alpha-2-macroglobulin) [NCBI Gene 2] {aka A2MD, CPAMD5, FWP007, S863-7}, TMOD3 (tropomodulin 3) [NCBI Gene 29766] {aka UTMOD}, AXL (AXL receptor tyrosine kinase) [NCBI Gene 558] {aka ARK, AXL3, JTK11, Tyro7, UFO}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, CALR (calreticulin) [NCBI Gene 811] {aka CALR1, CRT, HEL-S-99n, RO, SSA, cC1qR}, PTGFRN (prostaglandin F2 receptor inhibitor) [NCBI Gene 5738] {aka CD315, CD9P-1, EWI-F, FPRP, SMAP-6}, ITGA1 (integrin subunit alpha 1) [NCBI Gene 3672] {aka CD49a, VLA1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, MYL9 (myosin light chain 9) [NCBI Gene 10398] {aka LC20, MLC-2C, MLC2, MMIHS4, MRLC1, MYRL2}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, UCHL1 (ubiquitin C-terminal hydrolase L1) [NCBI Gene 7345] {aka HEL-117, HEL-S-53, NDGOA, PARK5, PGP 9.5, PGP9.5}, ADAMTS12 (ADAM metallopeptidase with thrombospondin type 1 motif 12) [NCBI Gene 81792] {aka PRO4389}, CAT (catalase) [NCBI Gene 847], CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, EPHA2 (EPH receptor A2) [NCBI Gene 1969] {aka ARCC2, CTPA, CTPP1, CTRCT6, ECK}, MMP3 (matrix metallopeptidase 3) [NCBI Gene 4314] {aka CHDS6, MMP-3, SL-1, STMY, STMY1, STR1}, PDLIM5 (PDZ and LIM domain 5) [NCBI Gene 10611] {aka ENH, ENH1, L9, LIM}, SPAG9 (sperm associated antigen 9) [NCBI Gene 9043] {aka CT89, HLC-6, HLC4, HLC6, JIP-4, JIP4}
- **Diseases:** UC (MESH:C536938), inflammation (MESH:D007249)
- **Chemicals:** paraformaldehyde (MESH:C003043), L-ascorbic acid 2-phosphate (MESH:C011669), Alamar Blue (MESH:C005843), Alexa Fluor  647 (MESH:C569686), lipid (MESH:D008055), EDTA (MESH:D004492), dexamethasone (MESH:D003907), amphotericin B (MESH:D000666), hyaluronic-acid (MESH:D006820), Alexa Fluor  488 (MESH:C000711379), Alexa Fluor  488;Novus (-), streptomycin (MESH:D013307), cetylpyridinium chloride (MESH:D002594), calcium (MESH:D002118), beta-glycerophosphate (MESH:C031463), fatty acid (MESH:D005227), CO2 (MESH:D002245), alphaMEM (MESH:C420642), Cy5.5 (MESH:C098793), NaCl (MESH:D012965), Alizarin Red S (MESH:C004468), Oil Red O (MESH:C011049), DMSO (MESH:D004121), penicillin (MESH:D010406)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** WJ — Homo sapiens (Human), Glioblastoma, Cancer cell line (CVCL_W352)

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13004360/full.md

---
Source: https://tomesphere.com/paper/PMC13004360